Why Progressive MS Resists Existing Therapies
Progressive MS fails to respond to immunomodulatory therapies approved for relapsing disease because it is driven by a fundamentally different biological mechanism: chronic compartmentalized CNS inflammation that operates independently of blood-brain barrier breakdown. This distinction — documented across multiple patent filings in the retrieved dataset — explains why agents that suppress peripheral immune activity have limited impact on disability accumulation in PPMS and SPMS.
The disease biology, as described explicitly in F. Hoffmann-La Roche patent filings, involves two concurrent but biologically distinct inflammatory mechanisms. The first is active inflammation — T- and B-cell infiltration across a permeable blood-brain barrier producing classical white matter lesions. The second, and more therapeutically challenging, is compartmentalized inflammation: subpial demyelination, slow expansion of pre-existing lesions, and diffuse chronic neuroinflammation in normal-appearing white and gray matter, all occurring without detectable blood-brain barrier disruption.
Chronic compartmentalized CNS inflammation in progressive MS — characterised by subpial demyelination, slow lesion expansion, and diffuse neuroinflammation without blood-brain barrier breakdown — is identified across multiple patent filings as the primary driver of disability accumulation independent of relapses.
This mechanistic framing has direct therapeutic consequences. Agents that deplete peripheral B cells (anti-CD20 antibodies such as ocrelizumab) cannot cross the blood-brain barrier and therefore cannot address the CNS-resident inflammatory compartment. The therapeutic rationale for CNS-penetrant agents — particularly BTK inhibitors — rests precisely on this gap. According to the European Medicines Agency, demonstrating benefit in progressive MS requires evidence of impact on disability accumulation, not merely relapse reduction, setting a high regulatory bar for this indication.
Compartmentalized CNS inflammation in progressive MS refers to diffuse neuroinflammation driven by CNS-resident immune cells (microglia, macrophages) and meningeal immune aggregates, operating behind an intact blood-brain barrier. It is distinct from the acute, BBB-dependent inflammation characteristic of relapsing MS and is largely inaccessible to peripherally-acting immunotherapies.
Key molecular targets documented across retrieved filings include BTK (expressed on B cells, myeloid cells, and microglia), LRP1 (a myelin debris receptor suppressing OPC differentiation via RhoA activation), LINGO-4 (a myelin inhibitory protein), Semaphorin 6A (a promoter of oligodendrocyte differentiation), and a multi-biomarker panel comprising NEFL, GFAP, CXCL13, MOG, CNTN2, FLRT2, and CXCL9 identified in an Octave Bioscience filing for disease progression monitoring.
BTK Inhibitors: The Most Contested IP Territory in Progressive MS
BTK inhibitors constitute the single largest cluster of retrieved patent filings in progressive MS, with at least 12 distinct patent records across multiple assignees and jurisdictions. The mechanistic argument — that BTK’s expression on both CNS microglia and peripheral B cells enables a dual-compartment therapeutic effect unavailable to anti-CD20 antibodies — is consistently articulated across filings from Roche, Principia Biopharma, and Genzyme.
Two BTK inhibitors are named in the progressive MS patent dataset: fenebrutinib (F. Hoffmann-La Roche), described at 200 mg twice daily in PPMS-directed filings, and tolebrutinib (Principia Biopharma / Sanofi), with active continuation filings extending from 2020 priority dates through a WO filing in March 2026.
The two named agents occupy distinct IP positions. Fenebrutinib, developed by F. Hoffmann-La Roche, is addressed in IL-jurisdiction filings (2022) that specify 200 mg twice daily as the active clinical dose and subdivide PPMS patients by T1-gadolinium and T2 lesion status — language consistent with an active or completed Phase 2/3 protocol. Tolebrutinib, originating from Principia Biopharma (acquired by Sanofi, filed through both Principia and Genzyme entities), has a continuation filing chain spanning 2020 provisional applications through a US filing in November 2024 and a WO filing in March 2026, with priority data referencing multiple provisional applications filed during 2024–2025. This sustained IP activity is consistent with ongoing Phase 3 clinical data generation.
“BTK inhibitors target both the peripheral adaptive immune response and CNS-resident innate immune activity in microglia — a dual-compartment mechanism not achievable by CD20-depleting antibodies that cannot cross the blood-brain barrier.”
The patient selection logic for anti-CD20 therapy in progressive MS is well-developed in Genentech/Roche filings: gadolinium-enhancing lesions (confirming residual active inflammation), age under 55, EDSS increase of at least 1 point over 2 years, and an MSSS above 5 are described as predictors of anti-CD20 response. The anti-CD20 family — ocrelizumab, rituximab, and ofatumumab — spans at least 10 Roche/Genentech filings across US, EP, AU, CA, SG, IN, IL, and BR jurisdictions. A 2023 IL filing describing weight-stratified ocrelizumab dosing (1.2 g for patients under 75 kg; 1.8 g for patients 75 kg or above at 6-month intervals) signals post-approval label optimisation activity.
Explore the full BTK inhibitor patent landscape for progressive MS in PatSnap Eureka.
Search BTK Inhibitor Patents in PatSnap Eureka →Remyelination Strategies: OPC Biology and the Open Therapeutic Window
Remyelination-directed approaches in the progressive MS patent landscape are patent-active but uniformly preclinical — representing an open therapeutic window with no clinical-stage agent evident in the retrieved dataset. The central biological target is the oligodendrocyte progenitor cell (OPC), whose differentiation into myelin-producing oligodendrocytes is suppressed by multiple inhibitory signals in the MS lesion environment.
LRP1 (low-density lipoprotein receptor-related protein 1) is identified in Novoron Bioscience patent filings as a myelin debris receptor whose activation suppresses OPC differentiation via pathological RhoA signalling; blocking LRP1 with receptor associated protein (RAP) is proposed to restore remyelination capacity in progressive MS.
The most developed remyelination IP cluster in this dataset belongs to Novoron Bioscience, with three filings (WO, CA, EP) describing RAP (receptor associated protein) as an LRP1 inhibitor. The mechanistic logic: myelin debris in progressive MS lesions activates LRP1 on OPCs, triggering RhoA-mediated cytoskeletal changes that block differentiation into mature oligodendrocytes. RAP or its derivatives are proposed to block this interaction, relieving the inhibition and restoring physiological OPC-to-oligodendrocyte maturation. As noted by the National Institutes of Health, remyelination failure is a key contributor to irreversible disability in progressive MS, making this pathway a high-priority research target.
Additional remyelination IP includes Biogen Idec filings claiming that semaphorin 6A (Sema6A) promotes oligodendrocyte differentiation and myelination, and that LINGO-4 antagonism treats demyelination. Case Western Reserve University’s filing targets the cholesterol biosynthesis pathway, claiming that accumulating specific delta-8,9-unsaturated sterol intermediates enhances OPC-to-oligodendrocyte maturation. Synaptogenix’s 2024 US patent for PKC activation via bryostatin-1 or bryologs claims mitigation of demyelination, initiation of remyelination, and reduction of neuroinflammation across all MS subtypes including PPMS and SPMS, with preclinical to early clinical signals. Two filings from Istituto Superiore di Sanita and IRBM S.p.A. (Italy, 2022) describe pharmacological screening of approved drug libraries to identify compounds capable of inducing neuroprotection and boosting remyelination potential in progressive MS.
The absence of clinical-stage remyelination agents in this dataset, combined with active patent staking by multiple organisations, signals that remyelination represents an open therapeutic window. According to the World Health Organization, MS affects approximately 2.8 million people globally, with progressive forms accounting for a substantial proportion of long-term disability burden — reinforcing the medical and commercial urgency of this unmet need.
Neuroprotection and Cell Therapy: From Small Molecules to Stem Cells
Neuroprotection in progressive MS encompasses a heterogeneous set of mechanisms — oxidative stress reduction, neurotrophic factor support, lymphocyte depletion, and cell replacement — with the shared goal of preventing axonal loss and disability accumulation. The retrieved dataset spans small molecules at clinical stage through to cell and gene therapies at preclinical IP-staking stage.
Small Molecule Neuroprotection
Laquinimod (Teva Pharmaceutical Industries) is represented by multiple filings in HK and CN jurisdictions describing 1.2 mg/day dosing as providing neuroprotection in MS patients, reducing brain atrophy and prolonging time to confirmed disability progression. Teva’s filings cite MRI-based outcome data and reference European Medicines Agency guidance on clinical endpoints, suggesting a Phase 2/3 data context. Cladribine (Merck Patent GmbH / Ares Trading S.A.) is addressed in multiple IL and CA filings for PPMS and SPMS, noting its selective lymphocyte-depleting activity. Notably, a Merck filing explicitly states that as of the filing date, no approved therapy exists for PPMS or SPMS, and proposes specific oral dosing regimens as investigational. A companion Ares Trading filing positions immune cell subtype ratios (T cells, B cells, NK cells) as predictive biomarkers for cladribine response — a precision medicine approach to lymphocyte-depleting therapy.
5-amino-2,3-dihydro-1,4-phthalazinedione (Metriopharm AG, EP patent 2022, active) claims to address oxidative stress, iron accumulation, and microglial activation — pathophysiological features specific to PPMS/SPMS that differ mechanistically from RRMS. GM-CSF is described in a CN filing as a neurodegeneration modulator, with neuroinflammation modulation cited as the primary mechanism; evidence is preclinical. University of Helsinki’s SG filing describes CDNF and MANF C-terminal fragments with neuroprotective potential in neurological disease contexts.
Merck, Teva, Roche, and Metriopharm all file explicitly for PPMS/SPMS indications separate from RRMS, reflecting both the regulatory distinction between these populations and the commercial value of progressive MS-specific labelling. This pattern signals that progressive MS is being treated as a distinct commercial opportunity requiring dedicated IP strategy, not merely a label extension of relapsing disease filings.
Cell and Gene Therapy Approaches
Several filings represent earlier-stage, innovation-frontier approaches that are actively staking IP positions in progressive MS. Children’s Medical Center Corporation (Boston) proposes PD-L1-expressing genetically modified hematopoietic stem cells (HSCs) to suppress CNS inflammation, with active PCT and US filings. Sana Biotechnology‘s IL filing (2022) describes hypoimmunogenic neural cells — MHC-I/II-reduced, CD47-expressing cells derived from pluripotent stem cells — designed to evade microglial recognition, explicitly targeting progressive MS. Sangamo BioTherapeutics‘ CN filing discloses MOG-specific CAR-Treg cells, with the filing explicitly noting compatibility with existing MS therapies including glatiramer acetate, ocrelizumab, natalizumab, alemtuzumab, and siponimod. A 2018 academic paper from the Mellen Center / Cleveland Clinic characterises MSC-derived neural progenitor cells for progressive MS as representing “great expectations” — exploratory interest rather than demonstrated clinical benefit.
Map the full neuroprotection and cell therapy patent landscape for progressive MS with PatSnap Eureka.
Explore Progressive MS Patents in PatSnap Eureka →A nasal anti-CD3 antibody approach (foralumab) for SPMS is also represented: a CN filing from Brigham and Women’s Hospital describes a clinical case of a 61-year-old SPMS patient on ocrelizumab treated with intranasal foralumab, with PET imaging, representing a reported clinical observation. This unconventional mucosal delivery route for immune tolerance induction in SPMS is an early but notable signal. Research published by Nature on regulatory T-cell approaches in autoimmune CNS disease provides broader scientific context for both the CAR-Treg and foralumab tolerance-induction strategies.
Cell and gene therapy approaches for progressive MS — including PD-L1+ hematopoietic stem cells (Children’s Medical Center Corporation), hypoimmunogenic neural cells (Sana Biotechnology), and MOG-specific CAR-Treg cells (Sangamo BioTherapeutics) — are at preclinical IP-staking stage, with no clinical-stage cell therapy evident in the retrieved progressive MS patent dataset.
Assignee Landscape and Strategic IP Positioning
The progressive MS patent landscape is heavily concentrated: a small number of large pharmaceutical companies dominate by filing volume, with a secondary tier of academic institutions and biotechs addressing specific therapeutic niches. Understanding the assignee structure is essential for freedom-to-operate analysis and competitive intelligence.
F. Hoffmann-La Roche AG / Genentech, Inc. is the dominant assignee by volume, with at least 15 patent records spanning progressive MS treatment methods (anti-CD20), BTK inhibition for PPMS (fenebrutinib), and ocrelizumab dosing regimens. Filings span AU, EP, IL, US, WO, IN, SG, CA, and BR jurisdictions, indicating a global IP strategy. Genzyme Corporation (Sanofi) represents the second-largest BTK inhibitor patent cluster, with at least 6 records across US, IL, WO, and TW jurisdictions for tolebrutinib in relapsing MS. Principia Biopharma filings (acquired by Sanofi) overlap with Genzyme’s portfolio, reflecting a coordinated IP position — the most recent filing has a priority date of August 2024 to February 2025 and a WO publication date of March 2026.
The secondary tier includes Merck Patent GmbH / Ares Trading S.A. (cladribine for PPMS/SPMS, IL and CA), Teva Pharmaceutical Industries (laquinimod for progressive MS, HK and CN), and Novoron Bioscience (RAP-based remyelination, WO/CA/EP — a dedicated remyelination-focused biotech). Biogen Idec is present in older filings addressing LINGO-4 antagonism and Sema6A-mediated myelination; more recent Biogen activity is not prominently represented in this dataset. Academic and non-commercial institutions contributing to the dataset include University of Helsinki (CDNF/MANF neuroprotective factors), Case Western Reserve University (cholesterol biosynthesis/OPC maturation), Children’s Medical Center Corporation/Boston (PD-L1+ HSC gene therapy), Istituto Superiore di Sanita (compound screening for progressive MS), Mayo Foundation for Medical Education and Research (CNDP1 polypeptide-based PPMS differentiation), and Sheba Medical Center/Tel Hashomer (RNA polymerase I pathway as MS course classifier).
Several combination and emerging therapeutic vectors are also signalled in the dataset. A WO filing from Victor Piryatinsky describes laquinimod combined with a phosphodiesterase-4 inhibitor for additive or synergistic effects in MS. A JP filing from Medical University of Vienna describes a combination of cyclotide (plant-derived cyclic peptide) and kappa opioid receptor ligands for remyelination, CNS lesion reduction, and neuropathic pain in MS. The Octave Bioscience CN filing describing NEFL, GFAP, CXCL13, and related biomarker panels signals that treatment stratification infrastructure is being built alongside therapeutic IP — creating ancillary IP opportunities in diagnostics. As noted by WIPO, the concentration of patent families in a small number of jurisdictions combined with active continuation filing strategies is a recognised indicator of competitive clinical-stage programs.
“Remyelination remains an early-stage but patent-active space with no clinical-stage agent evident in this dataset — representing an open therapeutic window with significant freedom-to-operate landscape questions.”
The strategic implications are clear across three dimensions. First, BTK inhibitors represent the most active commercial IP battleground in progressive MS in this dataset, with Roche/Genentech (fenebrutinib, PPMS) and Sanofi/Principia (tolebrutinib, RMS/all MS) pursuing non-overlapping but mechanistically aligned programs, and continuation filing activity through 2025–2026 consistent with Phase 3 enrollment or readout periods. Second, cell and gene therapy for progressive MS is entering the IP landscape with preclinical-stage filings from Sana Biotechnology, Children’s Medical Center Corporation, and Sangamo BioTherapeutics — freedom-to-operate may still be wide, but competitive intensity will increase as manufacturing scales. Third, biomarker-guided patient stratification is becoming a standard component of progressive MS IP, with Octave Bioscience’s multi-biomarker panel and Ares Trading’s cladribine biomarker filing suggesting that future regulatory submissions in progressive MS will require companion biomarker strategies. Researchers and IP professionals can explore the full patent landscape using PatSnap Eureka’s drug pipeline intelligence tools or access broader innovation data through the PatSnap platform.